Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome
NCT03383380
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
30
Enrollment
OTHER
Sponsor class
Conditions
Activated PI3K-delta Syndrome
Immunodeficiency Primary
Interventions
DRUG:
Rapamycin
Sponsor
Children's Hospital of Fudan University